ArticleNature communications2025
Independent origins and non-parallel selection signatures of triclabendazole resistance in Fasciola hepatica.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- A practical miracidial motility assay for assessing Fasciola hepatica sensitivity to compounds in vitro.International journal for parasitology. Drugs and drug resistance · 2026Article
- Triclabendazole and Other Fasciolicides: Resistance ofAnimals : an open access journal from MDPI · 2026Review
- Genetic diversity and host-symbiont cophylogenetic analysis ofCurrent research in parasitology & vector-borne diseases · 2026Article
- Fasciolosis, a foodborne zoonotic trematode infection in cattle in Bangladesh: multifaceted validation of parthenogenecity and anthelmintic efficacy.Parasite (Paris, France) · 2026Article
- Mitochondrial genome analysis supports zoonotic transmission of triclabendazole-resistant human fascioliasis in Peru.One health (Amsterdam, Netherlands) · 2025Article
- Structural Insights and Calcium-Switching Mechanism ofInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Triclabendazole (TCBZ) is the primary treatment for fascioliasis, a global foodborne zoonosis caused by Fasciola hepatica. Widespread resistance to TCBZ (TCBZ-R) in livestock and a rapid rise in resistant human infections are significant concerns. To understand the genetic basis of TCBZ-R, we sequenced the genomes of 99 TCBZ-sensitive (TCBZ-S) and 210 TCBZ-R adult flukes from 146 bovine livers in Cusco, Peru. We identify genomic regions of high differentiation (F
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.